# Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

> **NCT03890120** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 419 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Cilofexor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03890120
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-27
- **Primary completion:** 2022-11-10
- **Final completion:** 2022-12-23
- **Target enrollment:** 419 (ACTUAL)
- **Why stopped:** Following recommendation of the external Data Monitoring Committee, after it reviewed the results of a planned interim futility analysis.
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03890120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03890120, "Study of Cilofexor in Adults With Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03890120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*